The acquisition brings a first-in-class anti-CD122 antibody, FB102, into the immunology pipeline, targeting large unmet needs in vitiligo and celiac disease, with potential for broader autoimmune indications. The $2.2B cash deal leverages proven development and commercialization strategies to maximize impact and supports long-term growth ambitions.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.